Patent · US Active

Sialylated fetuin-A as a marker of immunotherapy efficacy

US10884002B2 · kind B2 · utility

0Cited by
1References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 23, 2015
Grant dateJan 5, 2021
Priority date
Expiry dateAug 8, 2037

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.